WO2023047274A1 - Extended release pharmaceutical compositions of dydrogesterone - Google Patents
Extended release pharmaceutical compositions of dydrogesterone Download PDFInfo
- Publication number
- WO2023047274A1 WO2023047274A1 PCT/IB2022/058867 IB2022058867W WO2023047274A1 WO 2023047274 A1 WO2023047274 A1 WO 2023047274A1 IB 2022058867 W IB2022058867 W IB 2022058867W WO 2023047274 A1 WO2023047274 A1 WO 2023047274A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extended release
- pharmaceutical composition
- pharmaceutically acceptable
- dydrogesterone
- release pharmaceutical
- Prior art date
Links
- 238000013265 extended release Methods 0.000 title claims abstract description 123
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 102
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical group C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 title claims abstract description 99
- 229960004913 dydrogesterone Drugs 0.000 title claims abstract description 98
- 150000003839 salts Chemical class 0.000 claims abstract description 75
- 229920000642 polymer Polymers 0.000 claims abstract description 62
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims description 57
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 238000007667 floating Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 230000003111 delayed effect Effects 0.000 claims description 30
- 239000011248 coating agent Substances 0.000 claims description 26
- 238000000576 coating method Methods 0.000 claims description 26
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 21
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- -1 carboxymethyl ethyl Chemical group 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 229920002125 Sokalan® Polymers 0.000 claims description 11
- 239000008187 granular material Substances 0.000 claims description 11
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000007884 disintegrant Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 229940081735 acetylcellulose Drugs 0.000 claims description 6
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 229920002301 cellulose acetate Polymers 0.000 claims description 6
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 235000015165 citric acid Nutrition 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 5
- 229920002148 Gellan gum Polymers 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229920001800 Shellac Polymers 0.000 claims description 4
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 4
- 235000010492 gellan gum Nutrition 0.000 claims description 4
- 239000000216 gellan gum Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 4
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000004208 shellac Substances 0.000 claims description 4
- 229940113147 shellac Drugs 0.000 claims description 4
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 4
- 235000013874 shellac Nutrition 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 125000005591 trimellitate group Chemical group 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 239000001361 adipic acid Substances 0.000 claims description 3
- 235000011037 adipic acid Nutrition 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 239000003086 colorant Substances 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000001530 fumaric acid Substances 0.000 claims description 3
- 235000011087 fumaric acid Nutrition 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 125000005498 phthalate group Chemical class 0.000 claims description 3
- 239000004014 plasticizer Substances 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 229940069328 povidone Drugs 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 2
- 229920008347 Cellulose acetate propionate Polymers 0.000 claims description 2
- DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- VHEMBTYWURNBQQ-UHFFFAOYSA-N butanoic acid;phthalic acid Chemical compound CCCC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O VHEMBTYWURNBQQ-UHFFFAOYSA-N 0.000 claims description 2
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 2
- 229920001727 cellulose butyrate Polymers 0.000 claims description 2
- 229920006218 cellulose propionate Polymers 0.000 claims description 2
- 229920000578 graft copolymer Polymers 0.000 claims description 2
- 230000001050 lubricating effect Effects 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical group 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-M phthalate(1-) Chemical compound OC(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-M 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000003826 tablet Substances 0.000 description 28
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 239000008188 pellet Substances 0.000 description 17
- 239000002552 dosage form Substances 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 11
- 239000006185 dispersion Substances 0.000 description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000186 progesterone Substances 0.000 description 6
- 229960003387 progesterone Drugs 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 239000000583 progesterone congener Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000007907 direct compression Methods 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000005550 wet granulation Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 229920000161 Locust bean gum Polymers 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 235000010420 locust bean gum Nutrition 0.000 description 2
- 239000000711 locust bean gum Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RJKFOVLPORLFTN-HQZYFCCVSA-N (8s,9r,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-HQZYFCCVSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 description 1
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 1
- 229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003153 Eudragit® NE polymer Polymers 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229920003137 Eudragit® S polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920003085 Kollidon® CL Polymers 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002230 Pectic acid Chemical class 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000000728 ammonium alginate Chemical class 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical class [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- WZNRVWBKYDHTKI-UHFFFAOYSA-N cellulose, acetate 1,2,4-benzenetricarboxylate Chemical compound OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.CC(=O)OCC1OC(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(COC(C)=O)O1.OC(=O)C1=CC(C(=O)O)=CC=C1C(=O)OCC1C(OC2C(C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(OC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)C(COC(=O)C=3C(=CC(=CC=3)C(O)=O)C(O)=O)O2)OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)C(OC(=O)C=2C(=CC(=CC=2)C(O)=O)C(O)=O)O1 WZNRVWBKYDHTKI-UHFFFAOYSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003844 drug implant Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 1
- FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- IQSHMXAZFHORGY-UHFFFAOYSA-N methyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound COC(=O)C=C.CC(=C)C(O)=O IQSHMXAZFHORGY-UHFFFAOYSA-N 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical class O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000010318 polygalacturonic acid Chemical class 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000000737 potassium alginate Chemical class 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical class [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 229940043266 rosin Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
Definitions
- the invention relates to an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more pharmaceutically acceptable excipients.
- Dydrogesterone also known as 6-dehydro-9p,10a-progesterone or as 9p,10a-pregna-4,6- diene-3, 20-dione, is a synthetic pregnane steroid and a derivative of progesterone and retroprogesterone (9p,10a-progesterone) having formula I.
- Dydrogesterone is a progestin medication which is used for treatment of irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Further, combined with an estrogenic substance, dydrogesterone can be applied in secondary amenorrhoea, dysfunctional uterine bleeding and post-menopausal complaints where endogenous progesterone deficiency is implicated.
- US Patent No. 7,683,047 disclose a method of treating endometrial hyperplasia in a subject, said method comprising: administering continuously and uninterruptedly for a first predetermined time period a first dose of a progestin agent to said subject; and administering continuously and uninterruptedly for a second predetermined time period a second dose of a progestin agent to said subject.
- US Patent Publication No. 20050020553 Al disclose a method of inhibiting spontaneous or habitual miscarriage, said method comprising administering to a female patient in need of such treatment an effective amount of at least one non-endogenous gestagen compound from the moment of ovulation on.
- US Patent Publication No. 20110152840 Al disclose a method for reducing the occurrence of preterm delivery, the method comprising: administering a pharmaceutical composition comprising a steroid hormone to a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery.
- US Patent Publication No. 20040202713 Al disclose a contraceptive method comprising sequentially administering a plurality of dosage units containing a hormone composition to a female of childbearing capability so as to provide the hormone composition in an amount which is effective to inhibit ovulation, wherein the hormone composition is dydroge sterone component or a combination of estrogen and dydrogesterone component.
- PCT Patent Publication No. 2012055840 Al disclose a pharmaceutical composition comprising a hormonal agent, a biocompatible zinc salt, and pharmaceutical acceptable excipients.
- PCT Patent Publication No. 2004019954 Al disclose an improved pharmaceutical preparation, for administration to a female in need of estrogen replacement, comprising a plurality of doses arranged in alternating standard dose estrogen phases and ultra-low dose estrogen phases.
- Russian Patent No. 2289409 disclose a method of rehabilitation after medical termination of pregnancy, characterized in that on the first day from the moment of expulsion of the ovum, the drug Multi-tabs-intensive is prescribed, 1 tablet for a month, from the 16th to the 25th day, the drug Duphaston is prescribed 10 mg 2 times a day.
- Currently approved formulation of dydrogesterone is in the form of immediate release tablet. Patients need to take tablets of dydrogesterone two times a day, i.e., in morning and evening. There are chances that patient may forget to take dose properly, i.e., either morning or evening dose, which can lead to decrease in patient compliance.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, and optionally one or more pharmaceutically acceptable excipients.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients
- the one or more floating agents is a gas generating agent selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate, citric acid, or a combination thereof.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising from lOmg to 50mg of dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition, and optionally one or more floating agents; wherein the total weight of the pharmaceutical composition is between 100 mg to 400mg.
- an extended release pharmaceutical composition comprising (a) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients; (b) a coating over said core which comprises one or more fdm forming polymer.
- the present invention provides an extended release pharmaceutical composition
- a core comprising: (i) an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more fdm forming polymers.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising: a) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more extended release polymers.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more pharmaceutically acceptable excipients; wherein the composition is prepared by direct compression, dry granulation, or wet granulation process.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients; wherein the composition is prepared by direct compression, dry granulation, or wet granulation process.
- the present invention provides a process of preparation of an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein said process comprises: (a) blending dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more floating agents to obtain a blend; (b) optionally granulating the blend; (c) lubricating the blend or granules; (d) compressing the lubricated blend or granules to form a tablet or filling the lubricated blend or granules in a capsule.
- the present invention provides a process of preparation of an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein said process comprises: (a) preparing a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more floating agents to obtain a blend; (b) coating the core with one or more extended release polymer; (c) compressing the coated core of step (b) to form a tablet or filling the lubricated blend or granules in a capsule.
- the present invention provides an extended release pharmaceutical composition
- a delayed release component comprising: i) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable excipients, and ii) a delayed release layer comprising one or more delayed release polymers, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
- Another aspect of the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition, and optionally one or more floating agents, wherein the pharmaceutical composition when taken orally once-a-day is bioequivalent to the immediate release tablet taken twice daily.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone, wherein said dydrogesterone or pharmaceutically acceptable salts thereof, has a particle size of Dio less than 10 microns, D50 less than 50 microns, D90 less than 100 microns.
- the present invention relates to an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more pharmaceutically acceptable excipients.
- extended release refers to slow release of drug over a time period, which may extend from about 2 hours to about 24 hours or more.
- the extended release includes but is not limited to sustained release, controlled release, delayed release, or modified release form.
- therapeutically effective amount or “effective amount” used interchangeably, is defined to mean the amount or quantity of the active drug, which is sufficient to elicit an appreciable biological response when administered to the patient. It will be appreciated that the precise therapeutic dose will depend on the age and condition of the patient, nature of the condition to be treated and will be at the ultimate discretion of the attendant physician.
- composition or “solid oral composition” or “dosage form” or “pharmaceutical composition” as used herein synonymously include tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, , microtablets in a capsule, minitablets in a capsule, granules in a capsule, pellets, pellets in a capsule, powder, granules, extrudes, pellets, beads or spheroids, suspension or any other suitable dosage form meant for oral, parenteral, topical, transdermal, mucosal, nasal, buccal, or sublingual administration to a patient, preferably oral.
- tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, , microtablets in a capsule, minitablets in a capsule, gran
- “pharmaceutically acceptable salt” or “salt” is used interchangeably in the context of the present invention.
- “Pharmaceutically acceptable salts” or “salts” as used in the context of the present invention refers to inorganic acids and inorganic salts may further includes alkali metal and alkaline earth metal salts.
- excipient or “pharmaceutically acceptable excipients” means a pharmacologically inactive component such as a diluent, disintegrant, carrier, and the like, of a pharmaceutical product.
- the excipients that are useful in preparing a dosages form are generally safe, non-toxic, and are acceptable for veterinary as well as human pharmaceutical use.
- Reference to an excipient includes both one excipient and more than one excipient.
- the pharmaceutically acceptable excipients may include one or more pharmaceutically acceptable excipients are selected from the group comprising of diluent/fdler, binder, surfactant, glidant, disintegrant, lubricant, film forming polymer, coloring agent/colorant, opacifier, plasticizer and/or combinations thereof.
- Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the dydrogesterone or pharmaceutically acceptable salts thereof is embedded in one or more extended release polymer.
- Another embodiment of the present invention provides an extended release pharmaceutical composition that comprises a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the core is coated with one or more extended release polymer.
- Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein the pharmaceutical composition comprising about lOmg to about 50mg of dydrogesterone or pharmaceutically acceptable salts, ester, solvates, polymorphs thereof.
- Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein said pharmaceutical composition releases less than 85% of dydrogesterone within 2 hours and not less than 75% of dydrogesterone is released within 16 hours.
- Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D90 less than 100 microns.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D50 less than 50 microns and D90 less than 100 microns.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- dydrogesterone or pharmaceutically acceptable salts thereof wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is Dio less than 10 microns, D50 less than 50 microns and D90 less than 100 microns.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- dydrogesterone or pharmaceutically acceptable salts thereof wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D90 between 30pm and 90pm; preferably between 65 pm and 85 pm, more preferably between 70 pm and 85 pm.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- dydrogesterone or pharmaceutically acceptable salts thereof wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is Dso between 10pm and 40pm; preferably between 15 pm and 25 pm, more preferably between 18 pm and 22 pm.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- dydrogesterone or pharmaceutically acceptable salts thereof wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is Dio between 1pm and 10pm; preferably between 2.0 pm and 5 pm, more preferably between 1.8 pm and 3.0 pm.
- Suitable fillers/ diluents include, without limitation, starch, com starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose (flowlac 90), cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof.
- a filler may be employed in an amount ranging from about 10% to about 80%, preferably from about 20% to about 80% by weight of the pharmaceutical composition.
- the diluent is microcrystalline cellulose in an amount ranging from 40% to about 80% by weight of the pharmaceutical composition.
- Suitable binders include, without limitation, microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K 30 or PVP90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, both preferably of medium to high viscosity, e.g. viscosity grades 3 or 6 cps, copovidone, pregelatinized starch and combinations thereof.
- PVP polyvinylpyrrolidone
- PEG polyethylene glycols
- a binder may be employed in an amount ranging from about 0.1% to about 20%, preferably from about 0.5% to about 15%, such as 1% to 10%, by weight of the pharmaceutical composition.
- Suitable lubricants include, without limitation, zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silica, aluminum or calcium silicate, stearic acid, cutina, PEG 4000-8000, talc and combinations thereof.
- a lubricant may be employed in an amount ranging from about 0.01% to about 10%, preferably from about 0. 1% to about 5%, by weight of the pharmaceutical composition.
- Suitable glidants include, without limitation, zinc stearate, colloidal silicon dioxide (e.g., Aerosil 200), magnesium trisilicate, powdered cellulose, starch, talc and combinations thereof.
- a glidant may be employed in an amount ranging from about 0.01% to about 10%, preferably from about 0.1% to about 5%, by weight of the pharmaceutical composition.
- Suitable disintegrants include, without limitation, carboxymethylcellulose calcium (CMC- Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL), croscarmellose sodium, sodium starch glycolate, polacrillin potassium, low substituted hydroxypropyl cellulose, alginic acid, sodium alginate and guar gum, most preferably crosslinked PVP (crospovidone), crosslinked CMC (Ac-Di- Sol), carboxymethyl starch-Na (pirimojel and explotab) and/or combinations thereof.
- a disintegrant is employed in an amount of 0.01 to 15%, such as of 0.05 to 12%, such as at least 0. 1 to 10%, by weight of the pharmaceutical composition.
- Suitable plasticizers include, without limitation, propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate, polyethylene glycol.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydroge sterone or pharmaceutically acceptable salts thereof, wherein the composition is free of binder, disintegrant, or both.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydroge sterone or pharmaceutically acceptable salts thereof, wherein the at least one extended release polymer is selected from the group consisting of water insoluble polymers, water soluble polymers, pH dependent polymers, pH independent polymers and mixtures thereof.
- Suitable extended release polymer includes hydrophilic or hydrophobic polymers comprise one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl alcohol, a wax, xanthan gum, gellan gum, shellac, rosin, zein (prolamine from com), povidone, kollidon SR (polyvinyl acetate and povidone), a poly(meth)acrylate, polyethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, polyethylene oxide, carbomer homopolymer, hydroxy
- the extended release pharmaceutical composition of the present invention comprises dydrogesterone or pharmaceutically acceptable salts thereof, hydroxypropyl methyl cellulose, and optionally one or more pharmaceutically acceptable excipients.
- the extended release pharmaceutical composition of the present invention comprises: (a) a core comprising: (i) an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, hydroxypropyl methyl cellulose, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more fdm forming polymers.
- immediate release refers to immediate release of drug is where the majority (e.g., substantially all or all) of the pharmaceutically active ingredient is released within a relatively short time, for example within 1 hour, preferably within 30 minutes, after oral ingestion.
- the extended release pharmaceutical composition of present invention is a gastroretentive dosage form.
- Gastroretentive dosage form can be swellable or floating or combination of both.
- a “floating gastroretentive dosage form” has a bulk density less than gastric fluids. Such dosage forms are “floating” in that they remain buoyant in the gastric fluids of the stomach for a targeted period of time.
- the floating dosage form is able to be retained in the stomach, while releasing an active agent. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility of drugs that are less soluble in a high pH environment.
- Gastro retentive delivery systems are designed to be retained in the stomach for a prolonged time and release their active ingredients and thereby enable sustained and prolonged input of the drug to the upper part of the gastrointestinal (GI) tract.
- GI gastrointestinal
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients.
- Suitable floating agents include sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid.
- the floating agent generates CO2 independent of a fed or fasted state of an individual.
- the extended release composition comprising floating agent provides a gastroretentive dosage form that possess improved pharmacokinetic profile by retaining the dosage form in the stomach for a prolonged period of time.
- the extended release composition comprises gasgenerating floating agents, e.g., carbonate and bicarbonate salts, that generate CO2 in presence of acidic gastric fluid such as citric acid.
- the core further comprises organic and/or inorganic acids that react with carbonate salts in an aqueous environment, e.g., at neutral pH or at a weakly acidic pH, and generate CO2 gas.
- the extended release composition of the present invention comprising at least one floating agent are stable, and provide efficient delivery of dydrogesterone in the GI tract due to the presence of a water-soluble polymer such as polyethylene oxide, xanthan gum, hydroxypropyl cellulose, carbopol, Cross-linked polyvinyl alcohol (PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyvinylpyrrolidone (PVP), Hydroxypropyl methyl cellulose (HPMC), Polylactic acid (PLA), Polyglycolic acid (PGA), Polyacrylic acid, Tragacanth, Methyl cellulose, Pectin, Guar gum, Karaya gum, Locust bean gum, etc., that swells via imbibition
- the extended release composition comprises both gas generating agents and water swellable polymers.
- the extended release gastroretentive dosage form of the present disclosure provides a controlled sustained release of the active agent for a period of about 8-16 hours, e.g., about 12 hours, under fed and fasted conditions.
- the ratio of extended release polymer and floating agent is 1: 1 to 1: 10.
- the present invention provides an extended release pharmaceutical composition
- a core comprising: (i) an extended release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more film forming polymers.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising: a) a core comprising dydroge sterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more extended release polymers.
- the extended release pharmaceutical composition of present invention is a delayed release pharmaceutical composition.
- delayed release refers to a delay or a time lag of 2 hours to 12 hours before the active ingredient is released from the composition after administration.
- the delayed release pharmaceutical composition of the present invention comprises: a) a core comprising dydroge sterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more delayed release polymers.
- the “delayed release polymer” is selected such that the therapeutically active agent will be released when the dosage form reaches the small intestine or a region in which the pH is greater than pH 4.5.
- Preferred coating includes pH-sensitive materials, which remain intact in the lower pH environment of the stomach, but which disintegrate or dissolve at the pH commonly found in the small intestine of the patient.
- the delayed release polymer coating material begins to dissolve in an aqueous solution at pH above 4.5.
- the pH-solubility behavior of the delayed release polymers of the present invention are such that significant dissolution of the delayed release polymer coating will not occur until the dosage form has emptied from the stomach.
- the pH of the small intestine gradually increases from about 4.5 to about 6.5 in the duodenal bulb to about 7.2 in the distal portions of the small intestine (ileum).
- the lag time between the administration and the onset of the release can be modified by altering the coating materials or the amount of coat applied.
- Suitable delayed release polymers includes pH dependent enteric polymers such as Eudragits, methacrylates, methacrylic acid-methylmethacrylate copolymers, methacrylic acid-ethylmethacrylate copolymers, partially neutralized (meth)acrylate copolymer, cellulose phthalates, Hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, polyvinyl alcohol-polyethylene glycol graft copolymers (Kollicoat®), vinyl acetate-vinylpyrrolidone copolymer (Kollidon® VA64), cellulose acetate phthalate, Eudragit L, Eudragit S, Eudragit® L 100-55, Eurdragit® L30 D-55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS), cellulose acetate trimellitate or shellac.
- pH dependent enteric polymers such as Eudragits, methacrylates, methacrylic acid-methylmethacryl
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising: (a) a delayed release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more delayed release polymers, and optionally one or more pharmaceutically acceptable excipients, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
- the extended release pharmaceutical composition of the present invention comprises: (a) a delayed release component comprising: i) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable excipients, and ii) a delayed release layer comprising one or more delayed release polymers, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
- component refers to a part or portion of the pharmaceutical composition.
- the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and optionally one or more pharmaceutically acceptable excipients; wherein the composition is prepared by direct compression, dry granulation, wet granulation process, melt granulation, or extrusion process.
- the present invention provides a process of preparation of extended release pharmaceutical composition of dydrogesterone, wherein said process comprises:
- the present invention provides a process of preparation of an extended release pharmaceutical composition of dydrogesterone, wherein said process comprises:
- a delayed release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more delayed release polymer, and optionally one or more pharmaceutically acceptable excipients;
- Another aspect of the present invention provides an extended release pharmaceutical composition
- Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein the extended release may be achieved by one or more of coating or embedding in matrix using hydrophilic or hydrophobic polymers or by attachment to ion-exchange resins. Further, extended release may be achieved by osmotic oral release technology also.
- the extended release pharmaceutical composition of the present invention further comprises a surfactant.
- the surfactants include but are not limited to anionic, cationic, non-ionic or amphoteric surfactants or those known to the person skilled in the art.
- Suitable surface active are poloxamer 188, polysorbate 80, Cremophore, Soluplus, lecithin and sodium lauryl sulfate.
- the pharmaceutical composition of the present is stable.
- stable or stability or stabilized means the dosages form is stable under 40°C/75% RH and/or 30°C/75% RH for at least six (06) months.
- the total impurity in the dosage form is not more than 5% after storing at 40°C/75% RH and/or 30°C/75% RH for at least six (06) months. Any individual impurity in the dosage form is not more than 0.5% after storing at 40°C/75% RH and/or 30°C/75% RH for at least six (06) months.
- Another embodiment of the present invention provides an extended release pharmaceutical composition
- an extended release pharmaceutical composition comprising dydrogesterone, wherein the said composition is used in the treatment of irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency.
- the said composition also used for secondary amenorrhoea, dysfunctional uterine bleeding and post-menopausal complaints where endogenous progesterone deficiency is implicated, in combination with an estrogenic substance.
- step (b) Lubricate the blend obtained from step (a) with lubricants.
- Example 1 The in vitro release study for the pharmaceutical composition disclosed in Example 1 and 2 was carried out in 900ml of 0.2% sodium lauryl sulfate in water, USP Type II apparatus at a speed of 50RPM.
- the dissolution data is given in Table 1.
- Table 1 Release Profile of Dydrogesterone SR Tablets 20 mg
- Tablets prepared according to example 3 shows stability over a period of 3 months.
- the stability data of tablets is shown in the Table-2 as follows: Table 2: Stability Data of dydrogesterone tablets (Example 2)
- step 3 Loaded the material of step 2 in a blender and mixed at suitable 10 RPM for 10 minutes to get a dry mix.
- step 4 Lubricated the pre-lubricated blend of step 4 with magnesium stearate for 10 minutes at 10 RPM.
- Example 5B, 6, 7, and 8 The in vitro release study for the pharmaceutical composition disclosed in Example 5B, 6, 7, and 8 was carried out in 900 ml of 0. IN HC1 containing 0.2% sodium lauryl sulfate, USP Type I apparatus at a speed of 100 RPM.
- the dissolution data is given in Table 1.
- step 4 Compacted to get sized granules. 5.
- step 4 Loaded the material of step 4 in a blender and mixed at suitable RPM to get a dry mix.
- step 7 Compressed the lubricated blend of step 3 and step 6 into bilayer tablets using suitable tools.
- step 4 Add talc to step 4 under continuous stirring. Allow it to stir. 5. Sift above dispersion of step 5 through suitable sieve.
- step 5 Dispersion of step 5 was used for drug coating on sugar spheres using bottom spray technique.
- step 12 Dispersion of step 12 was used to coat the previously drug coated pellets- 1 of step 8, using bottom spray technique to obtain Delayed Release pellets. 14. Dry the Delayed Release pellets using bottom spray technique.
- step 21 filling the lubricated Delayed Release pellets of step 16 and Immediate Release pellets of step 20 in capsules.
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more pharmaceutically acceptable excipients.
Description
EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF DYDROGESTERONE
FIELD OF THE INVENTION
The invention relates to an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more pharmaceutically acceptable excipients.
BACKGROUND OF THE INVENTION
Dydrogesterone, also known as 6-dehydro-9p,10a-progesterone or as 9p,10a-pregna-4,6- diene-3, 20-dione, is a synthetic pregnane steroid and a derivative of progesterone and retroprogesterone (9p,10a-progesterone) having formula I.
Dydrogesterone is a progestin medication which is used for treatment of irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Further, combined with an estrogenic substance, dydrogesterone can be applied in secondary amenorrhoea, dysfunctional uterine bleeding and post-menopausal complaints where endogenous progesterone deficiency is implicated.
There are several references known in the literature, which describe the different composition of dydrogesterone, which are used in the treatment of various diseases.
US Patent No. 7,683,047 disclose a method of treating endometrial hyperplasia in a subject, said method comprising: administering continuously and uninterruptedly for a first predetermined time period a first dose of a progestin agent to said subject; and administering
continuously and uninterruptedly for a second predetermined time period a second dose of a progestin agent to said subject.
US Patent Publication No. 20050020553 Al disclose a method of inhibiting spontaneous or habitual miscarriage, said method comprising administering to a female patient in need of such treatment an effective amount of at least one non-endogenous gestagen compound from the moment of ovulation on.
US Patent Publication No. 20110152840 Al disclose a method for reducing the occurrence of preterm delivery, the method comprising: administering a pharmaceutical composition comprising a steroid hormone to a pregnant female subject having no history of preterm delivery and exhibiting one or more risk factors for preterm delivery.
US Patent Publication No. 20040202713 Al disclose a contraceptive method comprising sequentially administering a plurality of dosage units containing a hormone composition to a female of childbearing capability so as to provide the hormone composition in an amount which is effective to inhibit ovulation, wherein the hormone composition is dydroge sterone component or a combination of estrogen and dydrogesterone component.
PCT Patent Publication No. 2012055840 Al disclose a pharmaceutical composition comprising a hormonal agent, a biocompatible zinc salt, and pharmaceutical acceptable excipients.
PCT Patent Publication No. 2004019954 Al disclose an improved pharmaceutical preparation, for administration to a female in need of estrogen replacement, comprising a plurality of doses arranged in alternating standard dose estrogen phases and ultra-low dose estrogen phases.
Russian Patent No. 2289409 disclose a method of rehabilitation after medical termination of pregnancy, characterized in that on the first day from the moment of expulsion of the ovum, the drug Multi-tabs-intensive is prescribed, 1 tablet for a month, from the 16th to the 25th day, the drug Duphaston is prescribed 10 mg 2 times a day.
Currently approved formulation of dydrogesterone is in the form of immediate release tablet. Patients need to take tablets of dydrogesterone two times a day, i.e., in morning and evening. There are chances that patient may forget to take dose properly, i.e., either morning or evening dose, which can lead to decrease in patient compliance. In contrast, administering a single dose of medication which releases active ingredient over an extended period of time as opposed to the administration of a number of single doses at regular intervals is convenient for patients. In extended release preparations, the dosage form continuously provide drug for absorption into the blood stream to replace the amount eliminated while the dosage form is passing through the gastrointestinal tract of the patient. In view of the above, it is therefore, desirable to provide an extended release pharmaceutical composition of Dydrogesterone which is stable, bioavailable, have desired release profde, and provides improved patient compliance. Furthermore, there exists a need to develop a process for the development of pharmaceutical composition which is efficient and more economical.
SUMMARY OF THE INVENTION
The present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, and optionally one or more pharmaceutically acceptable excipients.
According to one aspect, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients.
According to one more aspect, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients, wherein the one or more floating agents is a gas generating agent selected from the group consisting of sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate, citric acid, or a combination thereof.
According to another aspect, the present invention provides an extended release pharmaceutical composition comprising from lOmg to 50mg of dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition, and optionally one or more floating agents; wherein the total weight of the pharmaceutical composition is between 100 mg to 400mg.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising (a) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients; (b) a coating over said core which comprises one or more fdm forming polymer.
According to another aspect, the present invention provides an extended release pharmaceutical composition comprising: (a) a core comprising: (i) an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more fdm forming polymers.
According to one more aspect, the present invention provides an extended release pharmaceutical composition comprising: a) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more extended release polymers.
According to one more aspect, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more
pharmaceutically acceptable excipients; wherein the composition is prepared by direct compression, dry granulation, or wet granulation process.
According to one more aspect, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients; wherein the composition is prepared by direct compression, dry granulation, or wet granulation process.
According to another aspect, the present invention provides a process of preparation of an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein said process comprises: (a) blending dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more floating agents to obtain a blend; (b) optionally granulating the blend; (c) lubricating the blend or granules; (d) compressing the lubricated blend or granules to form a tablet or filling the lubricated blend or granules in a capsule.
According to another aspect, the present invention provides a process of preparation of an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein said process comprises: (a) preparing a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more floating agents to obtain a blend; (b) coating the core with one or more extended release polymer; (c) compressing the coated core of step (b) to form a tablet or filling the lubricated blend or granules in a capsule.
According to another aspect, the present invention provides an extended release pharmaceutical composition comprising: (a) a delayed release component comprising: i) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable excipients, and ii) a delayed release layer comprising one or more delayed release polymers, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition, and optionally one or more floating agents, wherein the pharmaceutical composition when taken orally once-a-day is bioequivalent to the immediate release tablet taken twice daily.
In one another aspect, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein said dydrogesterone or pharmaceutically acceptable salts thereof, has a particle size of Dio less than 10 microns, D50 less than 50 microns, D90 less than 100 microns.
DESCRIPTION OF THE INVENTION
The present invention relates to an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more pharmaceutically acceptable excipients.
The term ‘extended release’ as used herein refers to slow release of drug over a time period, which may extend from about 2 hours to about 24 hours or more. The extended release includes but is not limited to sustained release, controlled release, delayed release, or modified release form.
The term “therapeutically effective amount” or “effective amount” used interchangeably, is defined to mean the amount or quantity of the active drug, which is sufficient to elicit an appreciable biological response when administered to the patient. It will be appreciated that the precise therapeutic dose will depend on the age and condition of the patient, nature of the condition to be treated and will be at the ultimate discretion of the attendant physician.
The term “composition” or “solid oral composition” or “dosage form” or “pharmaceutical composition” as used herein synonymously include tablet such as mono-layered tablets, bilayered tablets, trilayered tablet, multilayer tablet, caplets, minitablets, microtablets, capsules, tablet in tablet, tablets in a capsule, , microtablets in a capsule, minitablets in a
capsule, granules in a capsule, pellets, pellets in a capsule, powder, granules, extrudes, pellets, beads or spheroids, suspension or any other suitable dosage form meant for oral, parenteral, topical, transdermal, mucosal, nasal, buccal, or sublingual administration to a patient, preferably oral.
The term “pharmaceutically acceptable salt” or “salt” is used interchangeably in the context of the present invention. “Pharmaceutically acceptable salts” or “salts” as used in the context of the present invention refers to inorganic acids and inorganic salts may further includes alkali metal and alkaline earth metal salts.
The term “excipient” or “pharmaceutically acceptable excipients” means a pharmacologically inactive component such as a diluent, disintegrant, carrier, and the like, of a pharmaceutical product. The excipients that are useful in preparing a dosages form are generally safe, non-toxic, and are acceptable for veterinary as well as human pharmaceutical use. Reference to an excipient includes both one excipient and more than one excipient. The pharmaceutically acceptable excipients may include one or more pharmaceutically acceptable excipients are selected from the group comprising of diluent/fdler, binder, surfactant, glidant, disintegrant, lubricant, film forming polymer, coloring agent/colorant, opacifier, plasticizer and/or combinations thereof.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the dydrogesterone or pharmaceutically acceptable salts thereof is embedded in one or more extended release polymer.
Another embodiment of the present invention provides an extended release pharmaceutical composition that comprises a core comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the core is coated with one or more extended release polymer.
Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein the pharmaceutical composition
comprising about lOmg to about 50mg of dydrogesterone or pharmaceutically acceptable salts, ester, solvates, polymorphs thereof.
Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein said pharmaceutical composition releases less than 85% of dydrogesterone within 2 hours and not less than 75% of dydrogesterone is released within 16 hours.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D90 less than 100 microns.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D50 less than 50 microns and D90 less than 100 microns.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is Dio less than 10 microns, D50 less than 50 microns and D90 less than 100 microns.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is D90 between 30pm and 90pm; preferably between 65 pm and 85 pm, more preferably between 70 pm and 85 pm.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is
Dso between 10pm and 40pm; preferably between 15 pm and 25 pm, more preferably between 18 pm and 22 pm.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the particle size of dydrogesterone or pharmaceutically acceptable salts thereof is Dio between 1pm and 10pm; preferably between 2.0 pm and 5 pm, more preferably between 1.8 pm and 3.0 pm.
Suitable fillers/ diluents include, without limitation, starch, com starch, potato starch, pregelatinized starch, dry starch, disaccharides, lactose (flowlac 90), cellulose, cellulose derivatives, such as silicified microcrystalline cellulose, microcrystalline cellulose, mannitol, sorbitol, xylitol, trehalose, colloidal silica, sucrose or other sugars or sugar derivatives, calcium hydrogen phosphate, dicalcium phosphate, low-substituted hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, and combinations thereof. When present, a filler may be employed in an amount ranging from about 10% to about 80%, preferably from about 20% to about 80% by weight of the pharmaceutical composition. In one embodiment, the diluent is microcrystalline cellulose in an amount ranging from 40% to about 80% by weight of the pharmaceutical composition.
Suitable binders include, without limitation, microcrystalline cellulose, polyvinylpyrrolidone (PVP), e.g., PVP K 30 or PVP90F, polyethylene glycols (PEG), e.g., PEG 4000, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, both preferably of medium to high viscosity, e.g. viscosity grades 3 or 6 cps, copovidone, pregelatinized starch and combinations thereof. When present, a binder may be employed in an amount ranging from about 0.1% to about 20%, preferably from about 0.5% to about 15%, such as 1% to 10%, by weight of the pharmaceutical composition.
Suitable lubricants include, without limitation, zinc stearate, magnesium stearate, sodium stearyl fumarate, calcium stearate, stearic acid, colloidal silica, aluminum or calcium silicate, stearic acid, cutina, PEG 4000-8000, talc and combinations thereof. When present, a lubricant may be employed in an amount ranging from about 0.01% to about 10%, preferably from about 0. 1% to about 5%, by weight of the pharmaceutical composition.
Suitable glidants include, without limitation, zinc stearate, colloidal silicon dioxide (e.g., Aerosil 200), magnesium trisilicate, powdered cellulose, starch, talc and combinations thereof. When present, a glidant may be employed in an amount ranging from about 0.01% to about 10%, preferably from about 0.1% to about 5%, by weight of the pharmaceutical composition.
Suitable disintegrants include, without limitation, carboxymethylcellulose calcium (CMC- Ca), carboxymethylcellulose sodium (CMC-Na), crosslinked PVP (e.g. crospovidone, polyplasdone XL or kollidon CL), croscarmellose sodium, sodium starch glycolate, polacrillin potassium, low substituted hydroxypropyl cellulose, alginic acid, sodium alginate and guar gum, most preferably crosslinked PVP (crospovidone), crosslinked CMC (Ac-Di- Sol), carboxymethyl starch-Na (pirimojel and explotab) and/or combinations thereof. A disintegrant is employed in an amount of 0.01 to 15%, such as of 0.05 to 12%, such as at least 0. 1 to 10%, by weight of the pharmaceutical composition.
Suitable plasticizers include, without limitation, propylene glycol, phthalates, polyethylene glycols, sebacates, or citrates such as dibutyl phthalate, diethyl phthalate, dibutyl sebecate, triethyl citrate, acetyl tributyl citrate, polyethylene glycol.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydroge sterone or pharmaceutically acceptable salts thereof, wherein the composition is free of binder, disintegrant, or both.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydroge sterone or pharmaceutically acceptable salts thereof, wherein the at least one extended release polymer is selected from the group consisting of water insoluble polymers, water soluble polymers, pH dependent polymers, pH independent polymers and mixtures thereof.
Suitable extended release polymer, without limitation includes hydrophilic or hydrophobic polymers comprise one or more of polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, a fatty acid, a fatty acid ester, an alkyl
alcohol, a wax, xanthan gum, gellan gum, shellac, rosin, zein (prolamine from com), povidone, kollidon SR (polyvinyl acetate and povidone), a poly(meth)acrylate, polyethylene oxide), polyuronic acid salts, cellulose ethers, xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum locust bean gum, alkali metal salts of alginic acid or pectic acid, sodium alginate, potassium alginate, ammonium alginate, polyethylene oxide, carbomer homopolymer, hydroxypropyl cellulose, hydroxy ethyl cellulose, hydroxypropyl methyl cellulose (e.g., HPMC K15M, HPMC K4M), carboxyvinyl polymers, polymerized gelatin, shellac, methacrylic acid copolymer type C NF, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propionate phthalate, polyvinyl acetate phthalate (PVAP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate, hydrogenated castor oil, stearic acid, hydrogenated vegetable oil, glyceryl behenate, glyceryl monostearate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethyl cellulose (CMEC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), and acrylic acid polymers and copolymers like methyl acrylate, ethyl acrylate, methyl methacrylate and/or ethyl methacrylate with copolymers of acrylic and methacrylic acid esters (Eudragit NE, Eudragit RL, Eudragit RS), Carbomer (e.g., Carbomer 97 IP) and the like. Polymer may be used from 0.1- 50% by weight of the composition, preferably 10-50% by weight of the composition.
According to one embodiment the extended release pharmaceutical composition of the present invention comprises dydrogesterone or pharmaceutically acceptable salts thereof, hydroxypropyl methyl cellulose, and optionally one or more pharmaceutically acceptable excipients.
According to another embodiment the extended release pharmaceutical composition of the present invention comprises: (a) a core comprising: (i) an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, hydroxypropyl methyl cellulose, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more fdm forming polymers.
The ‘immediate release” as used herein refers to immediate release of drug is where the majority (e.g., substantially all or all) of the pharmaceutically active ingredient is released within a relatively short time, for example within 1 hour, preferably within 30 minutes, after oral ingestion.
According to one embodiment the extended release pharmaceutical composition of present invention is a gastroretentive dosage form. Gastroretentive dosage form can be swellable or floating or combination of both.
As used herein, a “floating gastroretentive dosage form” has a bulk density less than gastric fluids. Such dosage forms are “floating” in that they remain buoyant in the gastric fluids of the stomach for a targeted period of time. The floating dosage form is able to be retained in the stomach, while releasing an active agent. Prolonged gastric retention improves bioavailability, reduces drug waste, and improves solubility of drugs that are less soluble in a high pH environment. Gastro retentive delivery systems are designed to be retained in the stomach for a prolonged time and release their active ingredients and thereby enable sustained and prolonged input of the drug to the upper part of the gastrointestinal (GI) tract.
According to one embodiment, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymers, one or more floating agents, and optionally one or more pharmaceutically acceptable excipients.
Suitable floating agents, without limitation includes sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate and citric acid. In certain embodiments, the floating agent generates CO2 independent of a fed or fasted state of an individual. The extended release composition comprising floating agent provides a gastroretentive dosage form that possess improved pharmacokinetic profile by retaining the dosage form in the stomach for a prolonged period of time.
As noted above, in certain embodiments, the extended release composition comprises gasgenerating floating agents, e.g., carbonate and bicarbonate salts, that generate CO2 in presence of acidic gastric fluid such as citric acid. In certain embodiments, the core further comprises organic and/or inorganic acids that react with carbonate salts in an aqueous environment, e.g., at neutral pH or at a weakly acidic pH, and generate CO2 gas. In other embodiments, the extended release composition of the present invention comprising at least one floating agent are stable, and provide efficient delivery of dydrogesterone in the GI tract due to the presence of a water-soluble polymer such as polyethylene oxide, xanthan gum, hydroxypropyl cellulose, carbopol, Cross-linked polyvinyl alcohol (PVA), Cross-linked polyvinyl pyrrolidone (PVP), Polyvinylpyrrolidone (PVP), Hydroxypropyl methyl cellulose (HPMC), Polylactic acid (PLA), Polyglycolic acid (PGA), Polyacrylic acid, Tragacanth, Methyl cellulose, Pectin, Guar gum, Karaya gum, Locust bean gum, etc., that swells via imbibition of water from gastric fluid to (1) increase the size of the composition to promote gastric retention, (2) partially control the release of drug by entrapping the drug in the swollen polymer, (3) support the membrane and maintain the integrity of the composition in a swollen state with a seal coat and/or by forming a layer beginning at the periphery of the pharmaceutical composition, and (4) entrap generated gas (e.g., CO2) to provide buoyancy. In other embodiments the extended release composition comprises both gas generating agents and water swellable polymers. In certain embodiments, the extended release gastroretentive dosage form of the present disclosure provides a controlled sustained release of the active agent for a period of about 8-16 hours, e.g., about 12 hours, under fed and fasted conditions.
According to another embodiment, the ratio of extended release polymer and floating agent is 1: 1 to 1: 10.
According to another embodiment, the present invention provides an extended release pharmaceutical composition comprising: (a) a core comprising: (i) an extended release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more
pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more film forming polymers.
According to another embodiment, the present invention provides an extended release pharmaceutical composition comprising: a) a core comprising dydroge sterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more extended release polymers.
According to one embodiment the extended release pharmaceutical composition of present invention is a delayed release pharmaceutical composition.
The term ‘delayed release’ as used herein refers to a delay or a time lag of 2 hours to 12 hours before the active ingredient is released from the composition after administration.
According to another embodiment, the delayed release pharmaceutical composition of the present invention comprises: a) a core comprising dydroge sterone or pharmaceutically acceptable salts thereof, optionally one or more floating agents, and one or more pharmaceutically acceptable excipients, and b) a coating over said core, wherein said coating comprises one or more delayed release polymers.
The “delayed release polymer” is selected such that the therapeutically active agent will be released when the dosage form reaches the small intestine or a region in which the pH is greater than pH 4.5. Preferred coating includes pH-sensitive materials, which remain intact in the lower pH environment of the stomach, but which disintegrate or dissolve at the pH commonly found in the small intestine of the patient. The delayed release polymer coating material begins to dissolve in an aqueous solution at pH above 4.5. The pH-solubility behavior of the delayed release polymers of the present invention are such that significant dissolution of the delayed release polymer coating will not occur until the dosage form has emptied from the stomach. The pH of the small intestine gradually increases from about 4.5 to about 6.5 in the duodenal bulb to about 7.2 in the distal portions of the small intestine (ileum). The lag time between the administration and the onset of the release can be modified by altering the coating materials or the amount of coat applied.
Suitable delayed release polymers, without limitation includes pH dependent enteric polymers such as Eudragits, methacrylates, methacrylic acid-methylmethacrylate copolymers, methacrylic acid-ethylmethacrylate copolymers, partially neutralized (meth)acrylate copolymer, cellulose phthalates, Hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, polyvinyl alcohol-polyethylene glycol graft copolymers (Kollicoat®), vinyl acetate-vinylpyrrolidone copolymer (Kollidon® VA64), cellulose acetate phthalate, Eudragit L, Eudragit S, Eudragit® L 100-55, Eurdragit® L30 D-55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS), cellulose acetate trimellitate or shellac.
According to one embodiment, the present invention provides an extended release pharmaceutical composition comprising: (a) a delayed release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more delayed release polymers, and optionally one or more pharmaceutically acceptable excipients, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
According to one embodiment, the extended release pharmaceutical composition of the present invention comprises: (a) a delayed release component comprising: i) a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable excipients, and ii) a delayed release layer comprising one or more delayed release polymers, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
The term “component” as used herein refers to a part or portion of the pharmaceutical composition.
According to another embodiment, the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more floating agents, and optionally one or more pharmaceutically acceptable excipients; wherein the composition
is prepared by direct compression, dry granulation, wet granulation process, melt granulation, or extrusion process.
According to another aspect, the present invention provides a process of preparation of extended release pharmaceutical composition of dydrogesterone, wherein said process comprises:
(a) preparing an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more floating agent;
(b) preparing immediate release component comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more floating agent;
(c) compressing the components (a) and (b) to form a bilayer tablet or filling the components
(a) and (b) in a capsule.
According to another aspect, the present invention provides a process of preparation of an extended release pharmaceutical composition of dydrogesterone, wherein said process comprises:
(a) preparing a delayed release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more delayed release polymer, and optionally one or more pharmaceutically acceptable excipients;
(b) preparing an immediate release component comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more pharmaceutically acceptable excipients;
(c) compressing the components (a) and (b) to form a bilayer tablet or filling the components (a) and (b) in a capsule.
Another aspect of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition, and optionally one or more floating agents, wherein the total weight of the pharmaceutical composition is between lOOmg to 400mg and the pharmaceutical composition when taken orally once-a-day is bioequivalent to the immediate release tablet taken twice daily.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein the extended release may be achieved by one or more of coating or embedding in matrix using hydrophilic or hydrophobic polymers or by attachment to ion-exchange resins. Further, extended release may be achieved by osmotic oral release technology also.
According to another embodiment the extended release pharmaceutical composition of the present invention further comprises a surfactant. The surfactants include but are not limited to anionic, cationic, non-ionic or amphoteric surfactants or those known to the person skilled in the art. Suitable surface active are poloxamer 188, polysorbate 80, Cremophore, Soluplus, lecithin and sodium lauryl sulfate.
The pharmaceutical composition of the present is stable. The term “stable or stability or stabilized” means the dosages form is stable under 40°C/75% RH and/or 30°C/75% RH for at least six (06) months. Further, the total impurity in the dosage form is not more than 5% after storing at 40°C/75% RH and/or 30°C/75% RH for at least six (06) months. Any individual impurity in the dosage form is not more than 0.5% after storing at 40°C/75% RH and/or 30°C/75% RH for at least six (06) months.
Another embodiment of the present invention provides an extended release pharmaceutical composition comprising dydrogesterone, wherein the said composition is used in the treatment of irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Further, the said composition also used for secondary amenorrhoea, dysfunctional uterine bleeding and post-menopausal complaints where endogenous progesterone deficiency is implicated, in combination with an estrogenic substance.
The present invention is further illustrated by the following examples which are provided merely to be exemplary of the invention and don’t limit the scope of the invention. Certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.
EXAMPLES:
Process:
(a) Dispense, sift and blend the dydrogesterone, extended release polymer and one or more pharmaceutically acceptable excipients.
(b) Lubricate the blend obtained from step (a) with lubricants.
(c) Compress the lubricated blend using suitable punches and dies.
(d) Coat the compress mixture obtained in step (c) with coating solution. Dissolution Study
The in vitro release study for the pharmaceutical composition disclosed in Example 1 and 2 was carried out in 900ml of 0.2% sodium lauryl sulfate in water, USP Type II apparatus at a speed of 50RPM. The dissolution data is given in Table 1. Table 1: Release Profile of Dydrogesterone SR Tablets 20 mg
Tablets prepared according to example 3 shows stability over a period of 3 months. The stability data of tablets is shown in the Table-2 as follows: Table 2: Stability Data of dydrogesterone tablets (Example 2)
Process:
1. All ingredients are weighed accurately.
2. All ingredients were sifted through appropriate sieves followed by mixing in a blender to get a blend.
3. Loaded the material of step 2 in a blender and mixed at suitable 10 RPM for 10 minutes to get a dry mix.
4. Pre-lubricated the dry mix for 10 minutes at 10 RPM with colloidal anhydrous silica to get a blend.
5. Lubricated the pre-lubricated blend of step 4 with magnesium stearate for 10 minutes at 10 RPM.
6. Compressed the lubricated blend into tablets.
7. Packed the tablets as per requirement.
Dissolution Study
The in vitro release study for the pharmaceutical composition disclosed in Example 5B, 6, 7, and 8 was carried out in 900 ml of 0. IN HC1 containing 0.2% sodium lauryl sulfate, USP Type I apparatus at a speed of 100 RPM. The dissolution data is given in Table 1.
Process:
1. Sifted Dydrogesterone, Microcrystalline cellulose and Hydroxypropyl methylcellulose /Carbomer/Polyethylene oxide/Xanthan gum, Sodium bicarbonate, citric acid through appropriate sieves followed by mixing in a blender to get a blend.
2. Separately sifted colloidal anhydrous silica through appropriate sieve and mixed with above blend.
3. Separately sifted Magnesium stearate through appropriate sieve and mixed with step 2.
4. Compacted to get sized granules. 5. Loaded the material of step 4 in a blender and mixed at suitable RPM to get a dry mix.
6. Pre-lubricated the dry mix with colloidal anhydrous silica to get a blend.
7. Lubricated the pre-lubricated blend of step 6 with magnesium stearate.
8. Compressed the lubricated blend into tablets.
9. Packed the tablets as per requirement.
Process:
(Component -1)
1. Sifted all the ingredients through appropriate sieves.
2. Added pre-sifted Dydrogesterone, Lactose monohydrate, Hypromellose
(K100M) and Hypromellose (K4M) in a suitable blender and mixed for suitable time.
3. Mixed the sifted silicon dioxide with step 2 in a suitable blender and mixed for suitable time. Added magnesium stearate to get Premix-1.
(Component -2)
4. Sifted all the ingredients through appropriate sieves.
5. Added pre-sifted Dydrogesterone and Lactose monohydrate in a suitable blender and mixed for suitable time.
6. Mixed the sifted silicon dioxide with step 5 in a suitable blender and mixed for suitable time. Added magnesium stearate and mixed again to get Premix-2.
7. Compressed the lubricated blend of step 3 and step 6 into bilayer tablets using suitable tools.
8. Took Isopropyl alcohol and added Opadry YS-1-7040 white under continuous stirring. Added methylene chloride (dichloromethane) under continuous stirring till homogeneous coating dispersion was obtained. Filtered the dispersion through 100 mesh nylon cloth and coated the tablets with the coating dispersion.
Process: The pharmaceutical composition was prepared by the process as described in Example 12.
Process:
(Drug Pellets)
1. Sifted all the ingredients through appropriate sieves. 2. Add Hydroxypropyl methylcellulose to purified water under continuous stirring. Allow to stir to form clear solution.
3. Add Dydrogestrone to Isopropyl and add to step 3 under continuous stirring. Allow it to stir.
4. Add talc to step 4 under continuous stirring. Allow it to stir. 5. Sift above dispersion of step 5 through suitable sieve.
6. Dispersion of step 5 was used for drug coating on sugar spheres using bottom spray technique.
7. Dry the drug coated pellets using bottom spray technique.
8. Sift the drug coated pellets from suitable sieves. Discard the retentions and fines and collect the pellets of suitable size.
(Delayed Release Component)
9. Add Triethyl citrate to purified Water under continuous stirring. Allow to stir to make solution.
10. Add Talc to above Solution under continuous stirring.
11. Add above dispersion to the Eudragit L30D55 dispersion under continuous stirring.
12. Sift above dispersion through suitable sieve.
13. Dispersion of step 12 was used to coat the previously drug coated pellets- 1 of step 8, using bottom spray technique to obtain Delayed Release pellets. 14. Dry the Delayed Release pellets using bottom spray technique.
15. Sift the Delayed Release pellets from suitable sieves. Discard the retentions and fines and collect the pellets of suitable size.
16. Lubricate above Delayed Release pellets with talc.
(Immediate Release Component) 17. Coat the previously drug coated pellets-2 of step 8, with film coating of Opadry in
Isopropyl Alcohol and Methylene Chloride using bottom spray technique.
18. Dry the Immediate Release pellets using bottom spray technique.
19. Sift the Immediate Release pellets from suitable sieves. Discard the retentions and fines and collect the pellets of suitable size. 20. Lubricate above Immediate Release pellets with talc.
(Capsule filling)
21. filling the lubricated Delayed Release pellets of step 16 and Immediate Release pellets of step 20 in capsules.
Claims
1. An extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and one or more pharmaceutically acceptable excipients.
2. The extended release pharmaceutical composition according to claim 1, wherein the composition further comprises floating agents selected from sodium carbonate, sodium bicarbonate, calcium carbonate, adipic acid, malic acid, tartaric acid, ascorbic acid, fumaric acid, maleic acid, succinic acid, sodium citrate, citric acid, combinations thereof.
3. The extended release pharmaceutical composition according to any of the preceding claims 1 or 2, wherein the pharmaceutical composition comprises from lOmg to 50mg of dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer in an amount from 5% to 50% by weight of total weight of the pharmaceutical composition and is selected from hydrophilic polymers, hydrophobic polymers, or combinations thereof, and wherein the total weight of the pharmaceutical composition is between 100 mg to 400mg.
4. The extended release pharmaceutical composition according to any of the preceding claims 1 to 3, wherein the ratio of the extended release polymer and the floating agent is 1: 1 to 1: 10.
5. The extended release pharmaceutical composition according to any of the preceding claims 1 to 4, wherein the extended release polymer is selected from hydroxylpropyl methyl cellulose, hydroxypropyl cellulose, xanthan gum, carbomer, polyethylene oxide, polyvinyl acetate, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate, ethyl cellulose, xanthan gum, gellan gum, povidone, gellan gum, hydroxy ethyl cellulose, carboxyvinyl polymers, cellulose butyrate phthalate, cellulose hydrogen phthalate, cellulose propionate phthalate, polyvinyl acetate phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate, dioxypropyl methylcellulose succinate, carboxymethyl ethyl
26
cellulose, hydroxypropyl methylcellulose acetate succinate, acrylic acid polymers and copolymers, or combinations thereof.
6. The extended release pharmaceutical composition according to any of the preceding claims 1 to 5, wherein the extended release pharmaceutical composition comprises a core comprising dydrogesterone or pharmaceutically acceptable salts thereof embedded in one or more extended release polymer.
7. The extended release pharmaceutical composition according to any of the preceding claims 1 to 6, wherein the extended release pharmaceutical composition comprises a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and wherein the core is coated with one or more extended release polymer.
8. The extended release pharmaceutical composition according to any of the preceding claims 1 to 7, wherein the extended release pharmaceutical composition comprises: (a) a core comprising: (i) an extended release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and one or more pharmaceutically acceptable excipients, and (ii) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients; (b) a coating over said core, wherein said coating comprises one or more fdm forming polymers.
9. The extended release pharmaceutical composition according to any of the preceding claims 1 to 8, wherein the extended release pharmaceutical composition comprises: (a) a delayed release component comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more delayed release polymers, and optionally one or more pharmaceutically acceptable excipients, and (b) an immediate release component comprising dydrogesterone or its pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients.
10. The extended release pharmaceutical composition according to claim 9, wherein the delayed release polymer is selected from the group consisting of methacrylates, methacrylic acid-methylmethacrylate copolymers, methacrylic acid-ethylmethacrylate copolymers,
partially neutralized (meth)acrylate copolymer, cellulose phthalates, hydroxypropyl methyl cellulose phthalate, polyvinyl acetate phthalate, polyvinyl alcohol-polyethylene glycol graft copolymers, vinyl acetate-vinylpyrrolidone copolymer, cellulose acetate phthalate, hydroxypropyl methylcellulose acetate succinate, cellulose acetate trimellitate, shellac, or combinations thereof.
11. The extended release pharmaceutical composition according to any of the preceding claims 1 to 10, wherein the particle size of dydroge sterone or pharmaceutically acceptable salts thereof is D90 less than 100 microns.
12. The extended release pharmaceutical composition according to any of the preceding claims 1 to 11, wherein the extended release pharmaceutical composition releases less than 85% of dydrogesterone within 2 hours and not less than 75% of dydrogesterone is released within 16 hours.
13. The extended release pharmaceutical composition according to any of the preceding claims 1 to 12, wherein one or more pharmaceutically acceptable excipients are selected from the group consisting of diluents, binders, surfactants, glidants, disintegrants, lubricants, film forming polymers, coloring agents, opacifiers, plasticizers, or combinations thereof.
14. The extended release pharmaceutical composition according to any of the preceding claims 1 to 13, wherein the extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, wherein the composition is free of binder or disintegrant or both.
15. The extended release pharmaceutical composition according to any of the preceding claims 1 to 14, wherein the extended release pharmaceutical composition when taken orally once-a-day is bioequivalent to the immediate release tablet taken twice daily.
16. A process for preparing the extended release pharmaceutical composition according to any of the preceding claims 1 to 15, wherein the process comprises: (a) blending dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, and optionally one or more floating agent to obtain a blend; (b) optionally
granulating the blend; (c) lubricating the blend or granules; (c) compressing the lubricated blend or granules to form a tablet or filling the lubricated blend or granules in a capsule.
17. A process for preparing the extended release pharmaceutical composition according to any of the preceding claims 1 to 16, wherein the process comprises: (a) preparing a core comprising dydrogesterone or pharmaceutically acceptable salts thereof and optionally one or more floating agents to obtain a blend; (b) coating the core with one or more extended release polymer or delayed release polymer; (c) compressing the coated core of step (b) to form a tablet or filling the lubricated blend or granules in a capsule.
29
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280064294.7A CN118019524A (en) | 2021-09-24 | 2022-09-20 | Dydrogesterone sustained release pharmaceutical composition |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN202111043335 | 2021-09-24 | ||
IN202111043335 | 2021-09-24 | ||
IN202211007938 | 2022-02-15 | ||
IN202211007938 | 2022-02-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023047274A1 true WO2023047274A1 (en) | 2023-03-30 |
Family
ID=85720180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/058867 WO2023047274A1 (en) | 2021-09-24 | 2022-09-20 | Extended release pharmaceutical compositions of dydrogesterone |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023047274A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117180214A (en) * | 2023-10-26 | 2023-12-08 | 杭州和泽坤元药业有限公司 | Dydrogesterone tablet composition and preparation method thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US20110159094A1 (en) * | 2009-12-25 | 2011-06-30 | Onn Liat | Extended release compositions for high solubility, high permeability active pharmaceutical ingredients |
US20150290222A1 (en) * | 2010-07-28 | 2015-10-15 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
-
2022
- 2022-09-20 WO PCT/IB2022/058867 patent/WO2023047274A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040185097A1 (en) * | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
US20110159094A1 (en) * | 2009-12-25 | 2011-06-30 | Onn Liat | Extended release compositions for high solubility, high permeability active pharmaceutical ingredients |
US20150290222A1 (en) * | 2010-07-28 | 2015-10-15 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
Non-Patent Citations (1)
Title |
---|
WANG LU, GUAN HAI-YUN, XIA HE-XIA, CHEN XIU-YING, ZHANG WEI: "Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding – ovulation dysfunction patients", WORLD JOURNAL OF CLINICAL CASES, vol. 8, no. 15, 6 August 2020 (2020-08-06), pages 3259 - 3266, XP093055878, ISSN: 2307-8960, DOI: 10.12998/wjcc.v8.i15.3259 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117180214A (en) * | 2023-10-26 | 2023-12-08 | 杭州和泽坤元药业有限公司 | Dydrogesterone tablet composition and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008282900B2 (en) | Pulsatile gastric retentive dosage forms | |
EP1121104B1 (en) | New controlled release oral formulations for rivastigmine | |
US6331316B1 (en) | Enteric coated pharmaceutical tablet and method of manufacturing | |
KR101699912B1 (en) | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix | |
US20050192259A1 (en) | Aldosterone antagonist compositions for release during aldosterone acrophase | |
JP2002533380A (en) | Dosage form containing porous particles | |
JP2015110604A (en) | Hrt formulation | |
HU226670B1 (en) | Method for producing orally administered, solid pharmaceutical products with controlled release of the active substance | |
JP2008303223A (en) | Oral pulsed dose drug delivery system | |
CN109310642B (en) | Oral medicine composition of mesalazine | |
JPH061716A (en) | Medical prescription having long-term releasability of active ingredient | |
JP2011500793A (en) | Combination of antiemetics and oral contraceptives | |
WO2019073477A1 (en) | Extended release pharmaceutical composition of apremilast | |
EP2884967A1 (en) | Pharmaceutical compositions of memantine | |
US9820936B2 (en) | Oral controlled release pharmaceutical compositions of Bepotastine | |
JP7021108B2 (en) | Oral pharmaceutical composition of nicotinamide | |
US20100221335A1 (en) | Sustained-release preparation and method for producing the same | |
WO2023047274A1 (en) | Extended release pharmaceutical compositions of dydrogesterone | |
EP1673073A1 (en) | Sustained-release formulations | |
JP2000128779A (en) | Controlled release medicine type preparation | |
TWI745598B (en) | Febuxostat controlled release composition and preparation method thereof | |
CN118019524A (en) | Dydrogesterone sustained release pharmaceutical composition | |
EP1558222A2 (en) | Pharmaceutical compositions containing venlafaxine | |
US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
CN113840595A (en) | A matrix composition comprising (S) -5-benzyl-N- (5-methyl-4-oxo-2, 3,4, 5-tetrahydrobenzo [ b ] [1,4] oxazepin-3-yl) -4H-1,2, 4-triazole-3-carboxamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22872311 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |